These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 18703528)

  • 21. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project).
    Martinsson K; Johansson A; Kastbom A; Skogh T
    Clin Exp Immunol; 2017 Apr; 188(1):53-62. PubMed ID: 27859022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors.
    Jørgensen KT; Wiik A; Pedersen M; Hedegaard CJ; Vestergaard BF; Gislefoss RE; Kvien TK; Wohlfahrt J; Bendtzen K; Frisch M
    Ann Rheum Dis; 2008 Jun; 67(6):860-6. PubMed ID: 17644543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases.
    Cook AD; Mackay IR; Cicuttini FM; Rowley MJ
    J Rheumatol; 1997 Nov; 24(11):2090-6. PubMed ID: 9375865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities.
    Ioan-Facsinay A; el-Bannoudi H; Scherer HU; van der Woude D; Ménard HA; Lora M; Trouw LA; Huizinga TW; Toes RE
    Ann Rheum Dis; 2011 Jan; 70(1):188-93. PubMed ID: 20736390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis.
    Dewint P; Hoffman IE; Rogge S; Joos R; Union A; Dehoorne J; Delanghe J; Veys EM; De Keyser F; Elewaut D
    Rheumatology (Oxford); 2006 Feb; 45(2):204-8. PubMed ID: 16188943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory characteristics of citrullinated telopeptides of type I and II collagens for autoantibody binding in patients with rheumatoid arthritis.
    Koivula MK; Aman S; Alasaarela E; Karjalainen A; Hakala M; Risteli J
    Rheumatology (Oxford); 2006 Nov; 45(11):1364-9. PubMed ID: 16632481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis.
    Mutlu N; Bicakcigil M; Tasan DA; Kaya A; Yavuz S; Ozden AI
    J Rheumatol; 2009 Mar; 36(3):491-500. PubMed ID: 19228660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis.
    Fusconi M; Vannini A; Dall'Aglio AC; Pappas G; Cassani F; Ballardini G; Frisoni M; Grassi A; Bianchi FB; Zauli D
    Aliment Pharmacol Ther; 2005 Nov; 22(10):951-5. PubMed ID: 16268969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
    Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
    Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis.
    Inui N; Enomoto N; Suda T; Kageyama Y; Watanabe H; Chida K
    Clin Biochem; 2008 Sep; 41(13):1074-7. PubMed ID: 18638466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies.
    Kogure T; Tatsumi T; Fujinaga H; Niizawa A; Terasawa K
    Mediators Inflamm; 2007; 2007():12367. PubMed ID: 17497027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predominance of IgG4 in prodromal bullous pemphigoid.
    Lamb PM; Patton T; Deng JS
    Int J Dermatol; 2008 Feb; 47(2):150-3. PubMed ID: 18211485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].
    Galati S; Beauvillain C; Renier G; Jeannin P; Masson C; Chevailler A
    Ann Biol Clin (Paris); 2008; 66(2):157-64. PubMed ID: 18390426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilizing self-prepared ELISA plates for a cross-population study of different anti-HBe IgG subclass profiles.
    Wang L; Tsai TH; Huang CF; Ho MS; Lin DB; Ho YC; Lin SS; Wei JC; Chou MC; Yang CC
    J Med Virol; 2007 May; 79(5):495-502. PubMed ID: 17385671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
    López-Longo FJ; Oliver-Miñarro D; de la Torre I; González-Díaz de Rábago E; Sánchez-Ramón S; Rodríguez-Mahou M; Paravisini A; Monteagudo I; González CM; García-Castro M; Casas MD; Carreño L
    Arthritis Rheum; 2009 Apr; 61(4):419-24. PubMed ID: 19333979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis.
    Montano-Loza A; Czaja AJ; Carpenter HA; Piette A; Murphy D; Shums Z; Burlingame R; Norman GL
    Autoimmunity; 2006 Jun; 39(4):341-8. PubMed ID: 16891223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways.
    Trouw LA; Haisma EM; Levarht EW; van der Woude D; Ioan-Facsinay A; Daha MR; Huizinga TW; Toes RE
    Arthritis Rheum; 2009 Jul; 60(7):1923-31. PubMed ID: 19565507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.